Skip to Content

Generic Glucotrol XL Availability

See also: Generic Glucotrol

Glucotrol XL is a brand name of glipizide, approved by the FDA in the following formulation(s):

GLUCOTROL XL (glipizide - tablet, extended release;oral)

  • Manufacturer: PFIZER
    Approval date: April 26, 1994
    Strength(s): 5MG [RLD] [AB], 10MG [RLD] [AB]
  • Manufacturer: PFIZER
    Approval date: August 10, 1999
    Strength(s): 2.5MG [RLD] [AB]

Has a generic version of Glucotrol XL been approved?

A generic version of Glucotrol XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Glucotrol XL and have been approved by the FDA:

glipizide tablet, extended release;oral

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: May 12, 2017
    Strength(s): 2.5MG [AB], 5MG [AB], 10MG [AB]
  • Manufacturer: PAR PHARM
    Approval date: September 20, 2013
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: UNIQUE PHARM LABS
    Approval date: December 29, 2016
    Strength(s): 2.5MG [AB], 5MG [AB], 10MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: September 8, 2003
    Strength(s): 5MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: November 7, 2003
    Strength(s): 10MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: March 27, 2006
    Strength(s): 2.5MG [AB]
  • Manufacturer: ZYDUS PHARMS
    Approval date: July 16, 2018
    Strength(s): 2.5MG [AB], 5MG [AB], 10MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Glucotrol XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for lowering blood glucose
    Patent RE44459
    Issued: August 27, 2013
    Assignee(s): Alza Corporation

    The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.

    Patent expiration dates:

    • March 26, 2019

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.